Safety and efficacy of oxybutynin in patients with hyperhidrosis: systematic review and meta-analysis of randomized controlled trials
Archives of Dermatological Research · 04.03.2023 · 315 (8) · 2215-2226
DOI: 10.1007/s00403-023-02587-5 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Archives of Dermatological Research, online erschienen am 04.03.2023. Verfasst von Mohamed El-Samahy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Group of Egypt, Cairo, Egypt. 20512017100695@medicine.zu.edu.eg. Hauptthemen laut MEDLINE: Quality of Life, Hyperhidrosis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Science, Technology & Innovation Funding Authority.
Abstract (Originalsprache)
Background
Sweating is a physiologic mechanism of human thermoregulation. Hyperhidrosis is defined as a somatic disorder where the sweating is exaggerated in an exact area because the sweat glands are hyperfunctioning. It negatively affects the quality of life of the patients. We aim to investigate patient satisfaction and the effectiveness of oxybutynin in treating hyperhidrosis.
Methods
We prospectively registered the protocol of this systematic review and meta-analysis on PROSPERO (CRD 42022342667). This systematic review and meta-analysis were reported according to the PRISMA statement guidelines. We searched three electronic databases (PubMed, Scopus, Web of Science) from inception until June 2, 2022, using MeSH terms. We include studies comparing patients with hyperhidrosis who received oxybutynin or a placebo. We assessed the risk of bias using the Cochrane risk of bias assessment tool (ROB2) for randomized controlled trials. The risk ratio was calculated for categorical variables, and the mean difference was calculated for continuous variables using the random effect model with 95% confidence intervals (CI).
Results
Six studies were included in the meta-analysis, with a total of 293 patients. In all studies, patients were assigned to receive either Oxybutynin or Placebo. Oxybutynin represented an HDSS improvement (RR = 1.68 95% CI [1.21, 2.33], p = 0.002). It also can improve the quality of life. There is no difference between oxybutynin and placebo regarding dry mouth (RR = 1.68 95% CI [1.21, 2.33], p = 0.002).
Conclusion
Our study suggests that using oxybutynin as a treatment for hyperhidrosis is significant and needs to be highlighted for clinicians. However, more clinical trials are needed to grasp the optimum benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Research Group of Egypt, Cairo, Egypt. 20512017100695@medicine.zu.edu.eg.
- Faculty of Medicine, Zagazig University, Zagazig, Egypt. 20512017100695@medicine.zu.edu.eg.
- Medical Research Group of Egypt, Cairo, Egypt.
- Faculty of Medicine, University of Oran, Ahmed Ben Bella 1, Oran, Algeria.
- Faculty of Medicine, October 6 University, Giza, Egypt.
- Al-Najah National University, Nablus, Palestine.
Förderung
- The Science, Technology & Innovation Funding Authority
Zitieren
APA
El-Samahy, M., Mouffokes, A., Badawy, M. M., Amro, S., Fayad, T., & Abdelwahab, O. A. (2023). Safety and efficacy of oxybutynin in patients with hyperhidrosis: systematic review and meta-analysis of randomized controlled trials. Archives of Dermatological Research, 315(8), 2215-2226. https://doi.org/10.1007/s00403-023-02587-5
Vancouver
El-Samahy M, Mouffokes A, Badawy MM, Amro S, Fayad T, Abdelwahab OA. Safety and efficacy of oxybutynin in patients with hyperhidrosis: systematic review and meta-analysis of randomized controlled trials. Archives of Dermatological Research. 2023;315(8):2215-2226. doi:10.1007/s00403-023-02587-5
BibTeX
@article{ElSamahy2023,
author = {El-Samahy, Mohamed and Mouffokes, Adel and Badawy, Marwa M and Amro, Sarah and Fayad, Taha and Abdelwahab, Omar Ahmed},
title = {Safety and efficacy of oxybutynin in patients with hyperhidrosis: systematic review and meta-analysis of randomized controlled trials},
journal = {Archives of Dermatological Research},
year = {2023},
volume = {315},
number = {8},
pages = {2215--2226},
doi = {10.1007/s00403-023-02587-5}
}
EUVIMED